6 known cases. View patent page →
Celgene asserted multiple patents, including the '554 patent, against Natco's lenalidomide ANDA No. 201452. The '554 claims were dismissed without prejudice by stipulation on March 26, 2015; the overall case settled with a consent judgment entered January 4, 2016, and terminated January 5, 2016.
Antitrust/pay-for-delay action citing US 8,288,415 as one of the patents-in-suit in an alleged monopolization scheme. Terminated on 2015-03-31.
Consolidated purchaser antitrust class action against Celgene concerning Revlimid and Thalomid; US 8,288,415 is cited as a patent-in-suit in the alleged pay-for-delay scheme. No termination date listed.
Antitrust action citing US 8,288,415; terminated and transferred out on 2020-12-02.
Clayton Act antitrust case against Celgene Corporation citing US 8,288,415 as a patent-in-suit. Terminated 2021-04-18.
Antitrust action against Celgene; patents listed: 8,288,415; 8,315,886; 8,404,717. Assigned to Judge Esther Salas and Magistrate Michael A. Hammer. No termination date listed as of Feb. 19, 2026.